Date: 2017-09-30
Type of
information: Initiation of the trial
phase: 1 - OLE
Announcement: initiation of the trial
Company: Bluebird bio (USA - MA)
Product: bb2121, anti-BCMA CAR T cells
Action
mechanism:
- cell therapy/immunotherapy product/gene therapy/CAR-T cell therapy. bb2121 is a chimeric antigen receptor T cell (CAR T) therapy targeting B cell maturation antigen (BCMA). Bluebird bio is developing bb2121 in collaboration with Celgene.
Disease: relapsed/refractory multiple myeloma
Therapeutic
area: Cancer - Oncology
Country:
Trial
details:
Latest
news:
- • On September 13, 2017, bluebird bio announced that the expansion cohort of the CRB-401 Phase 1 study of bb2121, an anti-BCMA CAR T therapy, has been initiated. The objective of the CRB-401 study is to evaluate the safety and efficacy of bb2121 in patients with relapsed/refractory multiple myeloma and determine a recommended Phase 2 dose.
- Patients in the expansion cohort will be treated at a dose range of 150 to 450 x 106 CAR+ T cells and will be required to have prior exposure to a proteasome inhibitor, an immunomodulatory agent and daratumumab.
Is
general: Yes
